• 1. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361

• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds C-nitro compounds
• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds Organic nitro compounds C-nitro compounds

Professional Introduction to Compound with CAS No. 1065074-89-6 and Product Name: 4-(3-Bromo-5-nitropyridin-2-yl)morpholine

The compound with CAS No. 1065074-89-6 and the product name 4-(3-Bromo-5-nitropyridin-2-yl)morpholine represents a significant advancement in the field of pharmaceutical chemistry. This compound, characterized by its unique structural framework, has garnered considerable attention due to its potential applications in medicinal chemistry and drug development. The molecular structure of this compound incorporates a pyridine ring substituted with bromine and nitro groups, combined with a morpholine moiety, which contributes to its distinctive chemical properties and reactivity.

In recent years, the exploration of heterocyclic compounds has been a cornerstone in the development of novel therapeutic agents. The pyridine derivative in 4-(3-Bromo-5-nitropyridin-2-yl)morpholine is particularly noteworthy, as it serves as a versatile scaffold for further chemical modifications. This flexibility allows researchers to tailor the compound’s pharmacological profile by introducing various functional groups or appending different substituents. Such modifications are essential for optimizing drug efficacy, solubility, and metabolic stability.

The bromo and nitro substituents on the pyridine ring play a crucial role in the compound’s reactivity and interaction with biological targets. These groups are often employed in medicinal chemistry to enhance binding affinity or to facilitate further functionalization through cross-coupling reactions. For instance, the presence of a bromo atom makes the compound susceptible to palladium-catalyzed coupling reactions, enabling the introduction of aryl or alkyl groups. Similarly, the nitro group can be reduced to an amine, providing another pathway for structural diversification.

Recent studies have highlighted the importance of morpholine derivatives in drug discovery. The morpholine ring is known for its ability to improve oral bioavailability and metabolic stability, making it a preferred scaffold in many pharmaceutical candidates. The integration of this moiety with a pyridine-based core in 4-(3-Bromo-5-nitropyridin-2-yl)morpholine creates a promising structure for further investigation. This combination not only enhances the compound’s solubility but also modulates its pharmacokinetic properties, potentially making it an attractive candidate for therapeutic applications.

The pharmaceutical industry has been increasingly interested in developing small-molecule inhibitors targeting various disease pathways. The structural features of 4-(3-Bromo-5-nitropyridin-2-yl)morpholine suggest its potential utility as an inhibitor or modulator of enzymes and receptors involved in metabolic disorders, inflammatory responses, or cancer progression. Preliminary computational studies have indicated that this compound may exhibit inhibitory activity against certain kinases or transcription factors, which are key players in these disease mechanisms.

In addition to its pharmacological potential, 4-(3-Bromo-5-nitropyridin-2-yl)morpholine has shown promise in material science applications. The unique electronic properties of its heterocyclic core make it a candidate for use in organic electronics or as a ligand in catalytic systems. Researchers have explored its use as a building block for synthesizing complex polymers or metal complexes with tailored functionalities. These applications underscore the versatility of this compound beyond traditional pharmaceutical uses.

The synthesis of 4-(3-Bromo-5-nitropyridin-2-yl)morpholine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic methodologies, such as transition-metal-catalyzed cross-coupling reactions and palladium-mediated transformations, have been employed to construct the desired molecular framework efficiently. These synthetic strategies not only ensure high yields but also minimize unwanted byproducts, making the process scalable for industrial production.

Evaluation of 4-(3-Bromo-5-nitropyridin-2-yl)morpholine in preclinical studies has provided valuable insights into its biological activity and safety profile. In vitro assays have demonstrated its interaction with specific biological targets, suggesting potential therapeutic benefits. Furthermore, animal models have been utilized to assess its pharmacokinetic behavior and toxicity levels. These studies are crucial for determining the feasibility of advancing this compound into clinical trials and eventual therapeutic use.

The development of novel drugs is often hampered by challenges such as poor solubility or rapid metabolism. However, the structural design of 4-(3-Bromo-5-nitropyridin-2-yl)morpholine addresses some of these issues through the incorporation of favorable pharmacokinetic features. The morpholine moiety enhances water solubility, while electronic modifications can fine-tune metabolic stability. Such improvements are critical for ensuring that drug candidates remain active within the body long enough to exert their intended therapeutic effect.

The future prospects for 4-(3-Bromo-5-nitropyridin-2-yl)morpholine are promising, with ongoing research aimed at expanding its applications and optimizing its properties further. Collaborative efforts between academic institutions and pharmaceutical companies are expected to yield new insights into its potential uses across multiple therapeutic areas. As our understanding of molecular interactions continues to grow, compounds like this one will play an increasingly important role in addressing unmet medical needs.

• 26163-05-3(3-Bromo-N,N-dimethyl-5-nitropyridin-2-amine)
• 1065074-87-4(3-Bromo-5-nitro-2-(piperidin-1-yl)pyridine)
• 1065074-81-8(3-Bromo-5-nitro-2-(pyrrolidin-1-yl)pyridine)
• 1259440-10-2(5-Bromo-N-(3-methoxypropyl)-N-methyl-3-nitropyridin-2-amine)
• 500300-74-3(N,N-Bis(2-methoxyethyl)-5-nitropyridin-2-amine)
• 863550-18-9(2-Pyridinamine, 3-bromo-N-butyl-N-(5-nitro-2-pyridinyl)-)
• 1065074-82-9(3-Bromo-2-(N,N-diethylamino)-5-nitropyridine)
• 505052-64-2(4-(5-Bromo-3-nitropyridin-2-yl)morpholine)
• 26820-62-2(4-(5-Nitropyridin-2-yl)morpholine)
• 1259440-06-6(4-(5-Bromo-3-nitropyridin-2-yl)-2,2-dimethylmorpholine)